Tag: Industry Trends
-
Wegovy Was Not First to Market: Evolution of GLP-1s
Wegovy arrived on the weight management scene with a clear advantage: it wasn’t the first GLP/GLP-GIP agent, but it raised the bar for efficacy and dosing convenience. This introduction to the market demonstrated that timing and product improvement are critical to success. Our discussion will trace the evolution from Byetta’s and Saxenda’s earlier dosing schedules… Read more
-
The TPP Guide: Unlocking Market Access in Biopharma
In the fast-paced business of biopharma, the journey from product discovery to market access is fraught with complexity. A Target Product Profile (TPP) serves not just as a blueprint for development but as a strategic compass across functions, including market access and pricing. As seasoned professionals know, a TPP’s value extends beyond clinical development into… Read more
-
5 Ways AI Will Revolutionize Pharma Market Access
The biopharmaceutical landscape is on the cusp of a transformative shift as artificial intelligence (AI), particularly Large Language Models (LLMs) and machine learning, take center stage in redefining market access strategies. In an industry where understanding and integrating complex data sets becomes pivotal, AI emerges as a potent ally. But what distinguishes AI from static… Read more
-
Understanding Drug Pricing Strategies with GLP-1 Agents
In the dynamic world of biopharma, understanding drug pricing strategies is more than just an academic exercise—it’s a crucial element of market success. Glucagon-like peptide 1 (GLP-1) agonists1 such as Novo Nordisk’s Ozempic, Novo Nordisk’s Wegovy, Eli Lilly’s Mounjaro, and Eli Lilly’s Zepbound offer a set of case studies that are helpful in illustrating common… Read more